Page 1 of 37
ONS ONCC CHEMO RENEWAL EXAM LATEST ACTUAL
EXAM 60 QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES|AGRADE
Neoadjuvant therapy does not increase survival when compared
to adjuvant therapy. It only changes the timing of treatment and
can change surgical options if the tumor is shrunk enough. If this
occurs, the patient may only require a lumpectomy plus radiation
therapy instead of needing a mastectomy .....ANSWER.....Main
benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and
mortality in the older patient. This assessment tool would
evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities,
cognitive function, nutritional status, polypharmacy, and a
medication review (NCCN Older Adult Oncology Guidelines,
,Page 2 of 37
version 1.2015). .....ANSWER.....Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric
assessment. You know that this assessment covers all but which of
the following:
65 .....ANSWER.....The NCCN Older Adult Oncology Guidelines
(version 1.2015) provides information on what is included in a
comprehensive geriatric assessment. Currently, more than 60% of
cancers in the United States occur in people age ______and
older and as the oncology world ages, nearly half (46%) of
cancer survivors are 70 years of age or older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner
will receive are categorized as irritants. Docetaxel can cause a
significant reaction if it extravasates. It can lead to edema,
erythema, occasional pain and blister formation (ONS
Chemo/Bio guidelines, 2014). That is the most likely reason that
Mrs. Turner was given a port for her treatments. Some patients
,Page 3 of 37
will receive their treatments through a peripheral IV without
incident. Just because they are intravenous agents does not mean
that a port is required and needing a port has nothing to do with
her being older in age. Since none of these agents are vesicants,
they likely could have been given safely via peripheral route but
having a port placed is OK as well. .....ANSWER.....What is your
best explanation for why Mrs. Turner was given a port to receive
her chemotherapy?
Irrirtants .....ANSWER....._____________can cause inflammation,
pain, and burning but rarely cause tissue necrosis comparable to
a vesicant (unless a large amount or a very high concentration of
the irritant is extravasated).
Vesicants .....ANSWER....._____________can cause blistering and
significant pain and tissue damage and destruction, leading to
tissue death.
, Page 4 of 37
Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug
deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the
antagonist to be ingested cellularly, leading to progressive tissue
destruction .....ANSWER.....A further classification of an
antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
ONS ONCC CHEMO RENEWAL EXAM LATEST ACTUAL
EXAM 60 QUESTIONS AND CORRECT DETAILED
ANSWERS WITH RATIONALES|AGRADE
Neoadjuvant therapy does not increase survival when compared
to adjuvant therapy. It only changes the timing of treatment and
can change surgical options if the tumor is shrunk enough. If this
occurs, the patient may only require a lumpectomy plus radiation
therapy instead of needing a mastectomy .....ANSWER.....Main
benefit of neoadjuvant chemotherapy (breast cancer patient)
A comprehensive geriatric assessment (CGA) is a multidisciplinary
evaluation to assess life expectancy and risk of morbidity and
mortality in the older patient. This assessment tool would
evaluate and include the following areas: functional status,
socioeconomic issues, psychosocial distress, comorbidities,
cognitive function, nutritional status, polypharmacy, and a
medication review (NCCN Older Adult Oncology Guidelines,
,Page 2 of 37
version 1.2015). .....ANSWER.....Due to Mrs. Turner's age and
comorbidities, her oncologist performs a comprehensive geriatric
assessment. You know that this assessment covers all but which of
the following:
65 .....ANSWER.....The NCCN Older Adult Oncology Guidelines
(version 1.2015) provides information on what is included in a
comprehensive geriatric assessment. Currently, more than 60% of
cancers in the United States occur in people age ______and
older and as the oncology world ages, nearly half (46%) of
cancer survivors are 70 years of age or older
Two of the agents (docetaxel and carboplatin) that Mrs. Turner
will receive are categorized as irritants. Docetaxel can cause a
significant reaction if it extravasates. It can lead to edema,
erythema, occasional pain and blister formation (ONS
Chemo/Bio guidelines, 2014). That is the most likely reason that
Mrs. Turner was given a port for her treatments. Some patients
,Page 3 of 37
will receive their treatments through a peripheral IV without
incident. Just because they are intravenous agents does not mean
that a port is required and needing a port has nothing to do with
her being older in age. Since none of these agents are vesicants,
they likely could have been given safely via peripheral route but
having a port placed is OK as well. .....ANSWER.....What is your
best explanation for why Mrs. Turner was given a port to receive
her chemotherapy?
Irrirtants .....ANSWER....._____________can cause inflammation,
pain, and burning but rarely cause tissue necrosis comparable to
a vesicant (unless a large amount or a very high concentration of
the irritant is extravasated).
Vesicants .....ANSWER....._____________can cause blistering and
significant pain and tissue damage and destruction, leading to
tissue death.
, Page 4 of 37
Non-DNA-binding solutions remain in the local area of the
extravasation, which improves the possibility of drug
deactivation.
DNA-binding agents attach to DNA nucleic acids, causing the
antagonist to be ingested cellularly, leading to progressive tissue
destruction .....ANSWER.....A further classification of an
antineoplastic agent's potential to cause damage is whether its
mechanism of action includes DNA binding.
Bendamustinea
Dactinomycin
Daunorubicin
Doxorubicin
Epirubicin
Idarubicin
Mechlorethamine
